金威醫療(08143.HK)年度收益約5535.3萬港元 同比增加約2.06%
格隆匯6月16日丨金威醫療(08143.HK)公吿,集團截至2023年3月31日止財政年度業績,收益約為5535.3萬港元,較去年增加約2.06%。經營業務經營虧損約為523.7萬港元(2022年:約589.1萬港元)。公司擁有人應占虧損淨額約為588.1萬港元。董事並不建議就截至2023年3月31日止年度派發末期股息(2022年:無)。
截至2023年3月31日止年度,集團於中國北京市營運一間綜合性醫院(2022年:兩間分別位於莆田及北京市綜合性醫院),主要從事提供綜合性醫院服務,包括(但不限於)醫院病房、手術室、身體檢查及檢驗。
管理層預見於未來數年,將可向公眾提供自普通疾病治療至治療特別及嚴重病症等更多元化便捷醫院服務,以滿足各類病患者的需求。因此,集團將繼續以其現有醫院或透過與戰略伙伴合作分配資源發展有關服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.